Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epidermal growth factor fusion toxin

Drug Profile

Epidermal growth factor fusion toxin

Alternative Names: DAB389-EGF; EGF diphtheria toxin chimeric protein

Latest Information Update: 18 Sep 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seragen
  • Developer Eli Lilly and Company; Seragen
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Coronary artery restenosis; Non-small cell lung cancer; Psoriasis; Solid tumours

Most Recent Events

  • 18 Sep 2006 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 13 Jun 2003 Preclinical trials in Solid tumours in USA (unspecified route)
  • 07 Feb 2001 Discontinued-II for Non-small cell lung cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top